59
Participants
Start Date
January 30, 2012
Primary Completion Date
September 29, 2015
Study Completion Date
December 30, 2016
Valganciclovir
Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant.
Stony Brook University Hospital, Stony Brook
Albany Medical Cancer Center, Albany
University at Buffalo, Buffalo
Drexel University Department of Nephrology, Philadelphia
Washington Hospital Center, Washington D.C.
Hospital Miguel Hidalgo, Aguascalientes
Medical College of Georgia, Augusta
University of Minnesota, Minneapolis
Mayo Clinic Rochester, Rochester
Instituto Mexicano de Trasplantes, Cuernavaca
Methodist Healthcare System of San Antonio, San Antonio
Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí City
National Institute of Transplantation, Los Angeles
University of California Los Angeles (UCLA), Los Angeles
University of California at San Francisco, San Francisco
Oregan Health & Science Univ, Portland
Tufts Medical Center, Boston
Western New England Renal & Transplant Associates, P.C., Springfield
Rhode Island Hospital, Providence
Hoffmann-La Roche
INDUSTRY